Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 04, 2015 6:47 PM ET

Professional Services

Company Overview of Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

Company Overview

Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. offers research and development in the areas of natural sciences, psychology, and humanities. The company also offers research in developmental and evolutionary biology and genetics, immunobiology and infection biology and medicine, cognition research, microbiology and ecology, neurosciences, structural and cell biology, astronomy, earth sciences and climate research, and social and behavioral sciences. Max-Planck-Gesellschaft was founded in 1948. It is based in Munich, Germany with institutes throughout Germany. It also has offices in Rome and Florence, Italy and in Nijmegen, Netherlands.

Hofgartenstrasse 8

Munich,  80539

Germany

Founded in 1948

Phone:

49 89 2108 0

Key Executives for Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

President
Age: 66
Compensation as of Fiscal Year 2015.

Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Key Developments

Actelion Ltd. Creates Vaxxilon Together with the Max Planck Society

Actelion Ltd. announced the creation of a start-up, together with the Max Planck Society, in the field of synthetic carbohydrate vaccines. The new company, Vaxxilon, aims to discover, develop, and commercialize synthetic carbohydrate vaccines. Vaxxilon has licensed exclusive rights to multiple preclinical vaccine candidates and additional technologies from Max-Planck Innovation GmbH, the technology transfer office of the Max Planck Society. The first preclinical candidates were discovered and synthesized by Prof. Dr. Peter Seeberger and his team at the Max Planck Institute of Colloids and Interfaces in Potsdam, Germany, near Berlin. An additional key component of the technology was jointly developed by Prof. Seeberger and Prof. Gennaro de Libero of the University Hospital of Basel. Vaxxilon plans to advance its first vaccine candidate into man within 3 years. Vaxxilon will be headquartered in Reinach, Switzerland, and a research facility will be established in Berlin.

Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Presents at Boston Biotech NY/NJ CEO Conference, Nov-13-2014 10:15 AM

Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Presents at Boston Biotech NY/NJ CEO Conference, Nov-13-2014 10:15 AM. Venue: Apella, 450 East 29th Street, New York, New York, United States. Speakers: Peter Gruss, President, Sabine Zimmermann.

Similar Private Companies By Industry

Company Name Region
hahn,consultants gmbh Europe
Kanzlei Jörn Schmidt Europe
TÜV SÜD Chemie Service GmbH Europe
Flick Gocke Schaumburg Europe
ISU Personaldienstleistungen GmbH Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., please visit www.mpg.de. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.